NCT05046080

Brief Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
5mo left

Started Aug 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Aug 2021Sep 2026

Study Start

First participant enrolled

August 6, 2021

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

August 25, 2021

Completed
22 days until next milestone

First Posted

Study publicly available on registry

September 16, 2021

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 29, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 29, 2026

Last Updated

February 19, 2026

Status Verified

February 1, 2026

Enrollment Period

5.2 years

First QC Date

August 25, 2021

Last Update Submit

February 17, 2026

Conditions

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

Outcome Measures

Primary Outcomes (1)

  • Clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix

    through study completion, an average of 1 year

Study Arms (1)

Observational (medical record review)

Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Other: Electronic Health Record ReviewOther: Laboratory Biomarker Analysis

Interventions

Laboratory Biomarker AnalysisOTHER

Correlative studies

Observational (medical record review)
Electronic Health Record ReviewOTHER

Medical records reviewed

Observational (medical record review)

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with clear cell carcinoma of the cervix, from January 1, 1985 to July 1, 2020

You may qualify if:

  • Patients diagnosed with clear cell carcinoma of the cervix at MDACC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

Study Officials

  • Anasis Malpica

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2021

First Posted

September 16, 2021

Study Start

August 6, 2021

Primary Completion (Estimated)

September 29, 2026

Study Completion (Estimated)

September 29, 2026

Last Updated

February 19, 2026

Record last verified: 2026-02

Locations

US(1)